Research & Reviews: Journal of Pharmaceutics and Nanotechnology

e-ISSN:2347-7857

Mesoporous Silica Nanoparticles: Versatile Platforms for Advanced Drug Delivery

Thomas J. Whitaker*

Department of Pharmaceutical Technology, Southern Coast University, Australia

Editorial

Received: 01-Dec-2025, Manuscript No. jpn-25-177953; **Editor assigned:** 03-Dec-2025, Pre-QC No. jpn-25-177953 (PQ); **Reviewed:** 17-Dec-2025, QC No. jpn-25-177953; **Revised:** 22-Dec-2025, Manuscript No. jpn-25-177953 (R); **Published:** 29-Dec-2025, DOI: 10.4172/2347-7857.13.009

***For Correspondence**

Thomas J. Whitaker, Department of Pharmaceutical Technology, Southern Coast University, Australia

E-mail: t.whitaker@scu-pharm.au

Citation: Thomas J. Whitaker, Mesoporous Silica Nanoparticles: Versatile Platforms for Advanced Drug Delivery. J Pharm Anal. 2025.13.009.

Introduction

Mesoporous silica nanoparticles (MSNs) are a class of nanomaterials characterized by their highly ordered porous structure, large surface area, and tunable pore size. Over the past two decades, MSNs have gained significant attention in nanomedicine due to their potential as drug delivery vehicles, imaging agents, and therapeutic platforms. Their unique structural properties allow high drug-loading capacity, controlled release, and surface functionalization, making them ideal for targeted and sustained drug delivery applications [1].

Discussion

The key feature of MSNs is their porous architecture, which enables the encapsulation of a wide range of therapeutic agents, including small molecules, proteins, and nucleic acids. The pore size can be adjusted during synthesis to optimize drug loading and release kinetics. Drugs can be physically adsorbed within the pores or chemically conjugated to the silica surface, providing flexibility in controlling release profiles. Surface modification with polymers, ligands, or antibodies further allows targeted delivery to specific cells or tissues, enhancing therapeutic efficacy and minimizing off-target effects [2,3].

MSNs are also highly biocompatible and can be engineered to degrade under physiological conditions, reducing long-term accumulation in the body. Stimuli-responsive MSNs have been developed to release drugs in response to pH, temperature, enzymes, or redox conditions, offering precise spatial and temporal control over drug delivery. Such features are particularly advantageous in cancer therapy, where controlled and targeted drug release can improve treatment outcomes while reducing systemic toxicity [4,5].

In addition to drug delivery, MSNs have applications in diagnostic imaging and theranostics. Their large surface area and functionalizable surface enable attachment of imaging agents, enabling simultaneous therapy and monitoring. The synthesis of MSNs is versatile, allowing scalable production with reproducible size, morphology, and porosity. However, challenges remain, including potential immunogenicity, nanoparticle aggregation, and the need for comprehensive toxicity assessment before clinical application.

Conclusion

Mesoporous silica nanoparticles offer a versatile and promising platform for advanced drug delivery and biomedical applications. Their tunable pore structure, high loading capacity, and ability to be functionalized for targeted and stimuli-responsive release make them powerful tools for improving therapeutic efficacy and patient outcomes. Continued research on biocompatibility, surface engineering, and clinical translation will be essential to fully harness the potential of MSNs in nanomedicine.

References

1. Williamson EJ, Walker AJ , Bhaskaran K, Bacon S , Bates C, et al. (2020) Factors associated with COVID-19-related death using OpenSAFELY, Nature. 584: p. 430-436.

2. Ioannou GN, Locke E , Green P, Berry K , Hare AMO, et al. (2020) Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. JAMA Netw Open 3: p. e2022310-e2022310.
3. Paizis G, Tikellis C, Cooper M E, Schembri J M, Le R A, et al. (2005) Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54: p. 1790-1796.
4. Fondevila MF, Mercado-Gómez M, Rodríguez A, Gonzalez-Rellan M J, Iruzubieta P, et al. (2021) Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol 74: p. 469-471.
5. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, et al. (2007) Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis. J Hepatol, 47: p. 387-395.

e-ISSN:2347-7857